A combined analysis using people of Japanese, Chinese, and European ancestry identified five new genes associated with the non-familial, sporadic form of amyotrophic lateral sclerosis (ALS).  These findings further an understanding of the genetic basis of sporadic ALS, and may support…

My heroes and role models come in all shapes and sizes. For example, Ruth Bader Ginsburg, who stood barely 5 feet tall, has always held a mighty spot in my mind. Best known as the second woman in U.S. history to be appointed a Supreme Court Justice, I admired…

The Motor Neurone Disease Association (MNDA) has begun a campaign in the U.K. calling for more accessible homes for people with motor neuron diseases, which includes amyotrophic lateral sclerosis (ALS), and a better system for delivering housing adaptations. Called Act to Adapt, the initiative follows the…

M102, a potential treatment for amyotrophic lateral sclerosis (ALS), is advancing into its first clinical study in patients through a partnership between researchers at England’s University of Sheffield Institute for Translational Neuroscience (SITraN) and Aclipse Therapeutics. This project is being supported in part by a $700,000 grant…

Three grants given researchers at two centers in Australia will advance work into ways of preserving nerve cells in people with amyotrophic lateral sclerosis (ALS), and other motor neuron diseases. The grants, totaling AU$1.5 million (about $1.1 million), came from FightMND, an Australian nonprofit patient advocacy group. Lezanne…

Novus Therapeutics has acquired Anelixis Therapeutics and its portfolio, including the antibody AT-1501, a potential treatment for amyotrophic lateral sclerosis (ALS) that the company is planning to move into a Phase 2 clinical trial for ALS and other diseases. AT-1501 is an antibody against a…

IPL344, Immunity Pharma‘s investigational therapy for amyotrophic lateral sclerosis (ALS), has a positive safety and tolerability profile and slows disease progression by about 50%, according to interim results from a small Phase 1/2a clinical trial. The company said it now is planning a placebo-controlled trial to evaluate IPL344…

The first patient has been dosed in a Phase 2a clinical trial evaluating the safety and effectiveness of ALZT-OP1a, a dry-powder inhaled formulation of cromolyn, in people with mild-to-moderate amyotrophic lateral sclerosis (ALS). The trial (NCT04428775) is recruiting up to 80 patients, ages 18–75, who have been…

Helixmith has selected Worldwide Clinical Trials to run a planned Phase 2 study of Engensis (VM202), its potential gene therapy for amyotrophic lateral sclerosis (ALS), according to a company press release. Engensis consists of a circular piece of DNA called a plasmid that carries instructions…

PrimeC is safe and well-tolerated for the treatment of amyotrophic lateral sclerosis (ALS) and shows potential to slow disease progression and lung function decline, according to interim results from a Phase 2a clinical trial. Given these results, developer NeuroSense Therapeutics will continue investigating PrimeC with additional analysis…